Israel - English - Ministry of Health

taro international ltd, israel - cinacalcet as hydrochloride - film coated tablets - cinacalcet as hydrochloride 90 mg - cinacalcet - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy. cinacalcet taro may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma. reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Israel - English - Ministry of Health

taro international ltd, israel - paracetamol - solution for infusion - paracetamol 10 mg/ml - paracetamol - short term treatment of moderate pain, especially following surgery and for short term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

taro international ltd, israel - sevelamer carbonate anhydrous - film coated tablets - sevelamer carbonate anhydrous 800 mg - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Israel - English - Ministry of Health

taro international ltd, israel - sevelamer carbonate anhydrous - film coated tablets - sevelamer carbonate anhydrous 800 mg - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - * prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.* prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), in adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

taro international ltd, israel - sevelamer carbonate anhydrous - powder for suspension - sevelamer carbonate anhydrous 2.4 g - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Israel - English - Ministry of Health

taro international ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - primary hypercholesterolemia: ezetimibe taro administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetimibe taro administered with a statin are indicated for use in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis). homozygous sitosterolemia (phytosterolemia): ezetimibe taro are indicated for use in patients with homozygous familial sitosterolemia.

Israel - English - Ministry of Health

taro international ltd, israel - tamsulosin hydrochloride - modified release capsules hard - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Israel - English - Ministry of Health

taro international ltd, israel - tamsulosin hydrochloride - modified release capsules hard - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Israel - English - Ministry of Health

taro international ltd, israel - doxorubicin hydrochloride - liposome concentrate for solution for infusion - doxorubicin hydrochloride 2 mg / 1 ml - doxorubicin - 1. first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease. 2. the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatment. 3. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. 4. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.